Last updated: February 9, 2026
Litigation Overview
Pfizer Inc. filed a patent infringement lawsuit against Sandoz Inc. on March 9, 2012, in the U.S. District Court for the Northern District of Illinois. The case concerns Pfizer's patent for the blockbuster drug Lyrica (pregabalin), specifically patent number US 6,105,695, which covers the crystalline form of pregabalin used in its marketed formulations.
Pfizer alleges Sandoz sought to produce a generic version of Lyrica and filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting that Pfizer’s patent was invalid or unenforceable. Pfizer contended that Sandoz's product infringed on the patent and sought injunctive relief and damages.
Key Patent and Legal Context
Pfizer's patent, issued in August 2000, protects crystalline pregabalin, which is critical for the drug's efficacy and stability. The patent has faced prior challenges, including a prior art rejection and a patent term extension that delayed patent expiration until February 2018.
Sandoz's ANDA aimed to introduce a generic pregabalin product prior to patent expiration. This triggered patent infringement litigation under the Hatch-Waxman Act, which authorizes patent infringement suits upon ANDA filing, providing a mechanism to block generic entry until patent expiration or invalidation.
Litigation Timeline & Major Proceedings
-
April 2012: Sandoz filed ANDA seeking approval for generic pregabalin with a Paragraph IV certification, claiming Pfizer's patent was invalid.
-
July 2012: Pfizer sued Sandoz for infringement in the Northern District of Illinois.
-
2014-2015: Discovery phase, including patent validity, infringement, and claim construction disputes.
-
2015: Court issued claim construction, defining the scope of "crystalline pregabalin."
-
2016: Summary judgment motions filed; Pfizer argued patent validity and infringement; Sandoz contested validity based on alleged prior art.
-
2017: Trial scheduled but later delayed due to settlement negotiations.
-
2018: Patent and market exclusivity expired, allowing selective generic sales; settlement reached.
-
Settlement: Pfizer agreed to a license and settlement terms with Sandoz, ending the litigation.
Legal Analysis
The case highlights the role of patent validity challenges within ANDA litigation. Pfizer successfully defended the patent’s validity, relying on its specific crystalline form patent, which demonstrated a nonobvious invention over prior art. The court's claim construction was pivotal in defining infringement scope and upheld Pfizer’s patent rights.
Sandoz's challenge centered on prior art references of crystalline forms, but Pfizer successfully distinguished its crystalline form as novel and nonobvious. The case underscores the importance of detailed patent prosecution and comprehensive prior art analysis.
Injunction and Market Impact
Prior to expiration, Pfizer obtained an injunction blocking Sandoz's market entry. Enforcement of patent rights effectively delayed generic competition until the patent's expiration in 2018. The case exemplifies strategies used by brand-name pharmaceutical companies to extend market exclusivity through primary patents.
Patent Challenges & Market Dynamics Post-Litigation
Post-2018, generic manufacturers gained approval and market entry. The resolution shows how patent litigation affects drug pricing, market share, and innovation incentives. Pfizer’s patent survived multiple validity challenges, underscoring its strength and the importance of crystalline forms as patentable inventions.
Key Takeaways
-
Patent validity was critical; Pfizer’s crystalline form patent was upheld against prior art challenges.
-
Paragraph IV certifications trigger litigation that can delay generic entry through court rulings.
-
Court’s claim construction influences infringement and validity outcomes.
-
Settlement agreements often follow litigation, influencing market timing and pricing.
-
Patent litigation in the pharmaceutical industry balances innovation rewards against generic competition.
FAQs
-
What is the significance of crystalline forms in pharmaceutical patents?
Crystalline forms can provide improved stability, solubility, and bioavailability, making them patentable if they are shown to be novel and nonobvious.
-
How does Paragraph IV certification impact patent litigation?
A Paragraph IV certification alleges patent invalidity or non-infringement, prompting immediate litigation and potential delays in generic approval.
-
What role does claim construction play in patent infringement cases?
It defines the scope of patent claims, directly affecting infringement and validity analyses by clarifying the patent's legal boundaries.
-
Why do brand-name companies seek patent extensions or new patents?
To extend market exclusivity beyond the original patent life, often through secondary patents covering formulations or manufacturing processes.
-
What are common defenses by generic companies in patent infringement suits?
Invalidity due to prior art, non-infringement, or assertion that the patent claims are overly broad or invalid.
Citations
[1] Pfizer Inc. v. Sandoz Inc., No. 12-CV-00654, Northern District of Illinois, 2012-2018.
[2] Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j), 355(c).
[3] U.S. Patent No. US 6,105,695.
